Publications

Nature

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

01-10-2019

Drug metabolism and disposition: the biological fate of chemicals

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.

16-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

03-09-2024

Clinical pharmacology and therapeutics

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails.

01-09-2024

British journal of cancer

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.

01-09-2024

Cancer chemotherapy and pharmacology

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

01-09-2024

Pediatric blood & cancer

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study.

01-09-2024

Clinical pharmacokinetics

Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence.

01-09-2024

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

30-08-2024

The Journal of infectious diseases

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa.

21-08-2024

British journal of clinical pharmacology

Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.

06-08-2024

Journal of pharmaceutical and biomedical analysis

ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Journal of pharmaceutical and biomedical analysis

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood.

01-08-2024

Clinical pharmacokinetics

Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease.

01-08-2024

Therapeutic drug monitoring

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

01-08-2024

Clinical pharmacokinetics

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.

01-07-2024

Clinical pharmacokinetics

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.

01-07-2024

European journal of drug metabolism and pharmacokinetics

The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.

01-07-2024

The Journal of antimicrobial chemotherapy

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.

01-07-2024

Cancer chemotherapy and pharmacology

Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data.

01-07-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.

20-06-2024

Journal of pharmaceutical and biomedical analysis

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

15-06-2024

Haematologica

IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia.

06-06-2024

ESMO open

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.

01-06-2024

Therapeutic drug monitoring

Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.

01-06-2024

Cancer medicine

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

01-06-2024

Cytotherapy

High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant.

01-06-2024

Pediatric rheumatology online journal

Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay.

07-05-2024

European journal of cancer (Oxford, England : 1990)

Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).

01-05-2024

EJNMMI physics

Quantification of biochemical PSA dynamics after radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

24-04-2024

EJNMMI radiopharmacy and chemistry

Automated radiolabelling of [⁶⁸Ga]Ga-PSMA-11 (gallium (⁶⁸Ga)-gozetotide) using the Locametz® kit and two generators.

17-04-2024

PLoS neglected tropical diseases

Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model.

01-04-2024

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Redispensing of expensive oral anticancer medicines: A practical application.

01-04-2024

Pharmaceutical research

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.

01-04-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

01-03-2024

European journal of nuclear medicine and molecular imaging

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [¹⁷⁷Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.

01-02-2024

Cancer chemotherapy and pharmacology

Are novel oral oncolytics underdosed in obese patients?

01-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Therapeutic drug monitoring

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

01-02-2024

Clinical and translational science

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

01-01-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

31-12-2023

Clinical and translational science

The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

01-12-2023

CPT: pharmacometrics & systems pharmacology

Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk.

01-12-2023

Pharmaceutical research

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

01-12-2023

The New England journal of medicine

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

09-11-2023

The Journal of antimicrobial chemotherapy

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.

06-11-2023

European journal of cancer (Oxford, England : 1990)

Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).

01-11-2023

Paediatric drugs

Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

01-11-2023

Therapeutic drug monitoring

Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.

01-10-2023

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models.

Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails.

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study.

Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence.

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa.

Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.

ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood.

Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.

The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.

Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data.

Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia.

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.

Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant.

Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay.

Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).

Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators.

Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model.

Redispensing of expensive oral anticancer medicines: A practical application.

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.

Are novel oral oncolytics underdosed in obese patients?

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk.

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.

Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).

Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.

This site uses cookies

Quantification of biochemical PSA dynamics after radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

Automated radiolabelling of [⁶⁸Ga]Ga-PSMA-11 (gallium (⁶⁸Ga)-gozetotide) using the Locametz® kit and two generators.

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [¹⁷⁷Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.

Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).